ultomiris 300 mg/3 ml koncentrat za otopinu za infuziju
amicus pharma d.o.o. - ravulizumab - koncentrat za otopinu za infuziju - 300 mg/3 ml - 1 bočica sa 3 ml koncentrata za otopinu za infuziju sadrži 300 mg ravulizumaba (100 mg/ml)
ultomiris 1100 mg/11 ml koncentrat za otopinu za infuziju
amicus pharma d.o.o. - ravulizumab - koncentrat za otopinu za infuziju - 1100 mg/11 ml - 1 bočica sa 11 ml koncentrata za otopinu za infuziju sadrži 1100 mg ravulizumaba (100 mg/ml)
ultomiris 300 mg/30 ml koncentrat za otopinu za infuziju
amicus pharma d.o.o. - ravulizumab - koncentrat za otopinu za infuziju - 300 mg/30 ml - 1 bočica sa 30 ml koncentrata za otopinu za infuziju sadrži 300 mg ravulizumaba (10 mg/ml)
ultomiris 300mg/30ml koncentrat za rastvor za infuziju
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - ravulizumab - koncentrat za rastvor za infuziju - 300mg/30ml
ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
qtrilmet
astrazeneca ab - метформина hidroklorid, Саксаглиптин, dapagliflozin - dijabetes mellitus, tip 2 - lijekovi koji se koriste u dijabetesu - qtrilmet prikazan u odraslih osoba u dobi od 18 godina i stariji sa dijabetesom tipa 2 za poboljšanje glikemijski kontrole pri metforminom ili bez sulfonilureje (su) i саксаглиптин ili dapagliflozin ne pruža adekvatne kontrole glikemijski . kad već liječenih metforminom i саксаглиптин i dapagliflozin.
hibibos t 0,5 g/100 ml otopina za kožu
bosnalijek d.d. - hlorheksidin - otopina za kožu - 0,5 g/100 ml - 100 ml otopine za kožu sadrži: 0,5 g klorheksidin diglukonata (u obliku 20 % otopine klorheksidin diglukonata)
ultomiris 1100mg/11 ml koncentrat za rastvor za infuziju
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - ravulizumab - koncentrat za rastvor za infuziju - 1100mg/11 ml
ultomiris 300mg/3ml koncentrat za rastvor za infuziju
druŠtvo za trgovinu na veliko farmaceutskim proizvodima "glosarij" d.o.o.-podgorica - ravulizumab - koncentrat za rastvor za infuziju - 300mg/3ml
sindroxocin 50mg prašak za rastvor za injekciju/infuziju
"evropa lek" doo podgorica - doksorubicin - prašak za rastvor za injekciju/infuziju - 50mg